CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein–Barr virus genes
-
Published:2021-10-19
Issue:
Volume:
Page:
-
ISSN:0340-7004
-
Container-title:Cancer Immunology, Immunotherapy
-
language:en
-
Short-container-title:Cancer Immunol Immunother
Author:
Sidorov SemjonORCID, Fux Lara, Steiner Katja, Bounlom Samyo, Traxel SabrinaORCID, Azzi TarikORCID, Berisha Arbeneshe, Berger ChristophORCID, Bernasconi MicheleORCID, Niggli Felix K.ORCID, Perner YvonneORCID, Pather SugeshneeORCID, Kempf WernerORCID, Nadal DavidORCID, Bürgler SimoneORCID
Abstract
AbstractEndemic Burkitt lymphoma (eBL) is an aggressive B cell cancer characterized by an IgH/c-myc translocation and the harboring of Epstein–Barr virus (EBV). Evidence accumulates that CD4 + T cells might contribute to eBL pathogenesis. Here, we investigate the presence of CD4 + T cells in primary eBL tissue and their potential dichotomous impact on an EBV-infected pre-eBL cell model using ex vivo material and in vitro co-cultures. In addition, we establish a novel method to study the effect of IgH/c-myc translocation in primary B cells by employing a CRISPR/Cas9 knock-in approach to introduce and tag de novo translocation. We unprecedently document that CD4 + T cells are present in primary eBL tumor tissue. Furthermore, we demonstrate that CD4 + T cells on the one hand suppress eBL development by killing pre-eBL cells lacking IgH/c-myc translocation in vitro and on the other hand indirectly promote eBL development by inducing crucial EBV Latency III to Latency I switching in pre-eBL cells. Finally, we show that while the mere presence of an IgH/c-myc translocation does not suffice to escape CD4 + T-cell-mediated killing in vitro, the CD4 + T-cell-mediated suppression of EBV’s Latency III program in vivo may allow cells harboring an IgH/c-myc translocation and additional mutations to evade immune control and proliferate by means of deregulated c-myc activity, resulting in neoplasia. Thus, our study highlights the dichotomous effects of CD4 + T cells and the mechanisms involved in eBL pathogenesis, suggests mechanisms of their impact on eBL progression, and provides a novel in vitro model for further investigation of IgH/c-myc translocation.
Funder
Krebsliga Schweiz Children's Research Center (CRC) of the University Children's Hospital Zurich Universität Zürich
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference45 articles.
1. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E (2007) Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7(3):166–175. https://doi.org/10.5555/afhs.2007.7.3.166 2. Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R, Nussenzweig MC (2012) Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 120(11):2240–2248. https://doi.org/10.1182/blood-2012-03-415380 3. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM (2014) Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a014282 4. Neiman PE, Thomas SJ, Loring G (1991) Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricius. Proc Natl Acad Sci USA 88(13):5857–5861. https://doi.org/10.1073/pnas.88.13.5857 5. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44(12):1321–1325. https://doi.org/10.1038/ng.2468
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|